The success of Sildenafil initially fueled a boom for major pharmaceutical companies, however recent changes present a complicated outlook for investors. Generic versions are eating into revenue, and ongoing legal battles add additional complexity to the landscape. While certain companies could still gain from related services, the overall direc… Read More